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Abstract The risk of developing breast cancer is increased
in women with family history of breast cancer and partic-
ularly in families with multiple cases of breast or ovarian
cancer. Nevertheless, many women with a positive family
history never develop the disease. Polygenic risk scores
(PRSs) based on the risk effects of multiple common genetic
variants have been proposed for individual risk assessment
on a population level. We investigate the applicability of the
PRS for risk prediction within breast cancer families. We
studied the association between breast cancer risk and a PRS
based on 75 common genetic variants in 52 Finnish breast
cancer families including 427 genotyped women and pedi-
gree information on *4000 additional individuals by
comparing the affected to healthy family members, as well
as in a case–control dataset comprising 1272 healthy pop-
ulation controls and 1681 breast cancer cases with infor-
mation on family history. Family structure was summarized
using the BOADICEA risk prediction model. The PRS was
associated with increased disease risk in women with family
history of breast cancer as well as in women within the
breast cancer families. The odds ratio (OR) for breast cancer
within the family dataset was 1.55 [95 % CI 1.26–1.91] per
unit increase in the PRS, similar to OR in unselected breast
cancer cases of the case–control dataset (1.49 [1.38–1.62]).
High PRS-values were informative for risk prediction in
breast cancer families, whereas for the low PRS-categories
the results were inconclusive. The PRS is informative in
women with family history of breast cancer and should be
incorporated within pedigree-based clinical risk assessment.
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Abbreviations
CI Confidence interval
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Introduction
Individualized risk prediction is a major goal of clinical
genetics. For prediction of breast cancer risk, family his-
tory is an important factor, women with a first-degree
relative having twofold increased risk [1], while women
from families with multiple breast/ovarian cancers or
cancers diagnosed at younger age experience a much
higher risk of developing the disease [2]. Rare mutations in
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high- and moderate-risk genes including BRCA1, BRCA2,
TP53, PTEN, PALB2, and CHEK2 explain about 20 % of
the familial relative risk for breast cancer [3]. A polygenic
component comprising many variants of small effect con-
tributes to the risk of developing the disease in the general
population and may also modify the risk in cancer families
[3–5].
Over the last few years, genome-wide association
studies (GWAS) have been successful in identifying some
of the common low-penetrance variants predisposing to
breast cancer [6–8]. To date, more than seventy variants
have been identified, which together explain about 14 % of
the familial risk of breast cancer [5, 6]. Individually, the
effect sizes associated with these common variants are
small. However, their combined effect, summarized as a
polygenic risk score (PRS), is more substantial [5]. In a
recent population-based case–control study, eight percent
of women at the high end of the PRS distribution were
found to fall into a group of intermediate life-time risk
(17–30 %) according to the UK NICE guidelines [9]. In
recent studies, the PRS has been tested in combination with
other risk prediction methods, such as BOADICEA and
BRCAPRO [10], mammographic density (BI-RADS) [11],
and a combination of family history and established risk
factors (BCRAT and IBIS) [10].
The contribution of the PRS to disease risk for indi-
viduals with family history of breast cancer and within
breast cancer families has not been studied extensively.
Here, we investigate the association between a 75-variant
PRS and disease status in individuals with and without
family history in a large Finnish case–control study and 52
Finnish breast cancer families, which have an extensive
pedigree information available and which have been well
characterized in terms of their genetic and pathological
characteristics. We use a family history score based on the
BOADICEA risk prediction algorithm to evaluate whether
the PRS predicts disease status among women sharing
similar family history, and discuss clinical utility of the
PRS for risk prediction in familial breast cancer.
Patients and methods
Study subjects
We included two separate sets of study subjects in the
analyses. The case–control dataset consisted of
i: three series of consecutive, unselected breast
cancer patients (n = 1303) enrolled for their first
primary breast cancer at the Helsinki University
Central Hospital during 1997–1998, 2000, and
2001–2004 as described previously [12–14],
ii: additional index cases (n = 378) with positive
family history of breast cancer (one per family),
tested negative for germ-line mutations in high
penetrance susceptibility genes BRCA1 and BRCA2
from an ongoing collection started at 1995 at the
Helsinki University Central Hospital, Department
of Clinical Genetics [15, 16],
iii: and healthy population controls (n = 1272, blood
donors, Finnish Red Cross) (Supplementary
Table 1).
In the case–control dataset, the index cases with positive
family history of breast cancer were categorized into two
groups based on whether they came from a family with two
breast cancers in first-degree relatives (later referred to as
‘‘small families’’) or from a family with three or more cases
of breast or ovarian cancer in first- or second-degree rela-
tives (later, ‘‘large families’’).
The breast cancer family dataset consisted of 493 (427
women) genotyped study subjects and registry data for fur-
ther 3992 family members from 52 Finnish families with
multiple cases of breast cancer, collected systematically as
described previously [16] (Supplementary Table 1). The
criteria for including families in this study were the highest
possible number of informative study subjects (women with
breast cancer) with available DNA sample. The families
were traced back to find the most recent common ancestors of
the breast cancer patients and then traced forward including
in the pedigree all the descendants of the most recent com-
mon ancestors according to records of church parish reg-
istries, Population Register Center, and Finnish Cancer
Registry. The age and disease status were ascertained up to
31st December 2010. The index case of each family had
previously been tested for germline mutations inBRCA1 and
BRCA2 mutations and was found to be negative [16]. The
number of family members varied between 22 and 356
(median 57.5) (Supplementary Table 2). Median proportion
of affected women born between 1910 and 1970 was 22 %
(Supplementary Table 2). The mean follow-up age of
genotyped healthy women was 60.3 years, and the mean
diagnosis age of genotyped breast cancer patients was
54.1 years. Seven pedigrees originated from two unrelated
founder couples. One of the moderate-penetrance mutations,
CHEK2:c.1100delC, PALB2:c.1592delT, or putative mod-
erate penetrance mutation FANCM:c.5101C[T, was trans-
mitted in seven families.
Genotyping
DNA was extracted from peripheral blood samples and
genotyped at CNIO genotyping unit, Madrid, or Ge´nome
Que´bec Innovation Centre using a custom Illumina Infi-
nium array, which was designed for the Collaborative
464 Breast Cancer Res Treat (2016) 158:463–469
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Oncological Gene-environment Study (COGS). Data
quality was monitored as described earlier [6]. Analyses
were based on 75 variants reported to be associated (at
P\ 5 9 10-8) in the analysis of the COGS dataset or
previous publications [5–8], with either overall breast
cancer or ER-negative disease (Supplementary Table 3).
All variants used in the risk score passed quality control
filters. For the majority of variants, genotypes were missing
in\0.1 % of individuals. Four variants used in the risk
score (rs17879961, rs10941679, rs4973768, and
rs13281615) had\0.4 % missing rate, and for one geno-
type, rs2943559, 1.06 % of individuals had missing geno-
types. Twelve samples with missing genotype calling for
over 10 % of the susceptibility variants were excluded
from further analyses.
In the analyses, the genotype of each variant was rep-
resented by allele dose (the number of copies of the rare
allele). Missing genotypes were imputed for controls using
the mean of the known genotype doses, and for cases using
the following formula:
¼ 2  ðp  ;Þð1  pÞ þ ðp  ;Þ
 
;
where Ø is the effect size (per-allele Odds Ratio) for
association between that variant and breast cancer risk in
the case–control dataset, and p is the minor allele fre-
quency in controls for the missing variant.
Three moderate-penetrance mutations, which are rela-
tively frequent in the Finnish population, CHEK2:c.1100-
delC, PALB2:c.1592delT, and FANCM:c.5101C[T, had
previously been genotyped locally using a custom made
TaqMan assay (Applied Biosystems, Thermo Fisher Sci-
entific Inc.), AmpliFluor fluorescent genotyping (KBio-
sciences), conformation sensitive gel electrophoresis
heteroduplex conformation analysis and Sanger sequencing
[17], or with the Sequenom MassARRAY system using
iPLEX Gold assays, respectively, as described previously
[18–20]. All study subjects of the case–control dataset were
genotyped for all three moderate-penetrance mutations.
However, in the breast cancer family dataset, the index
case in each family was genotyped. If a mutation was
found, all family members were genotyped for that muta-
tion. If no mutation was found, all family members were
considered as noncarriers.
Statistical analyses
Polygenic risk score
Statistical analyses were performed using R version 3.0.2
[21], including packages multiwayvcov [22] and lmtest
[23]. A PRS summarizing the risk effects associated with
75 common breast cancer susceptibility variants [6–8] was
calculated for each individual using the following formula:Pn
i¼1
ai log ORi; where n is the number of loci included in the
model, a is the number of disease alleles at locus, i and OR
is the corresponding per-allele odds ratio for breast cancer
(Supplementary Table 3). The ORs for each variant, used
as weights in the PRS, were taken from previously pub-
lished estimates from the Breast Cancer Association Con-
sortium (BCAC) [5]. The case–control component of the
present study was included in this estimation, but it only
comprised a small fraction (3 %) of the total BCAC data
available for estimation of the ORs. To avoid ascertain-
ment bias, studies oversampling for cases with family
history were excluded from this estimation. The PRS-val-
ues were standardized by the mean (0.50) and standard
deviation (0.45) of the PRS-values in healthy population
controls, so that odds ratios could be reported as per unit
standard deviation of the PRS. This corresponded well to a
recently introduced PRS of 77 common variants [5],
although we did not include data for two imputed variants
on 11q13 (rs78540526 and rs75915166). When study
subjects were categorized into centiles of the PRS distri-
bution, the centile boundaries were defined on the basis of
the PRS distribution in healthy population controls.
BOADICEA score
Familial history was quantified with a single quantity,
which we term a BOADICEA score. This was calculated
for all genotyped women (n = 427) in the 52 breast cancer
families by applying the BOADICEA risk prediction
algorithm [24]. The BOADICEA algorithm is implemented
in a modified version of MENDEL [25], coded in FOR-
TRAN 90. BOADICEA is a genetic model for breast and
ovarian cancer that models risk in terms of BRCA1 and
BRCA2 mutations and a polygene representing a large
number of loci of small effect to capture the residual
familial aggregation of breast cancer. The polygenotype is
assumed to be normally distributed, but this is implemented
using a binomial approximation, with transmission deter-
mined by a discrete hypergeometric polygenic model [26].
Thus, BOADICEA codes the polygenotype as a discrete
variable (0–6). The polygenic score for each discrete
polygenotype is the mean value from a standard normal
distribution over the same probability interval. The BOA-
DICEA algorithm can compute the posterior probability for
each polygenotype, conditional on their family history. The
overall BOADICEA score used in this analysis was cal-
culated by summing the scores for the discrete polygeno-
types weighted by the posterior probability. Hence, the
BOADICEA score is an estimate of the mean polygenotype
for the individual, given their family history (and hence
would predict their future cancer risk, although it is not
Breast Cancer Res Treat (2016) 158:463–469 465
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identical to the cancer risk output by the BOADICEA
program, which also depends on age). The score was cal-
culated assuming women were tested negative for the
mutations in the BRCA1 and BRCA2 genes, with sensi-
tivities of 0.7 and 0.8 for BRCA1 and BRCA2 testing,
respectively. The study subject (target) was coded unin-
formative with regard to age and disease status (in effect,
computing the mean polygenotype at birth, given the
family history). Other available information on birth year,
age, and cancer diagnoses of her relatives were included in
the calculations as in the BOADICEA data form. For data
standardizing purposes, only first-, second-, and third-de-
gree relatives of the same and older generations were
included in the input pedigrees.
Association analyses
Association between breast cancer risk and the PRS was
modeled using logistic regression. Analysis performed
within the breast cancer families (affected vs. healthy
women) was adjusted for age (diagnosis age for cases,
follow-up age for healthy women) and family history as
summarized by the BOADICEA score, and additionally for
moderate-penetrance mutations in CHEK2, PALB2, and
FANCM (separate terms for each mutation, coded as 0,
noncarriers; 1, heterozygotes; 2, homozygotes). P-values
and 95 % confidence intervals (CI) were corrected using
robust variance estimation, clustering the study subjects in
families. Association between PRS and the tumor estrogen
receptor (ER) expression was assessed with logistic
regression after categorizing the study subjects into quin-
tiles of the PRS distribution. Association between PRS and
age at diagnosis was examined by linear regression. Pear-
son’s r was used as a measure of correlation in comparisons
between PRS and BOADICEA scores.
Results
Association between PRS and case–control status
The combined effect of 75 variants with confirmed asso-
ciations with breast cancer risk was captured by con-
structing a PRS for each individual. The PRS was
associated with the increased risk of breast cancer in uns-
elected patient series and within breast cancer families
(Table 1, Supplementary Fig. 1). When healthy population
controls were used as a reference group, the odds ratio
(OR) for association between the PRS and breast cancer
risk was lower for sporadic cases (OR: 1.41, 95 % CI
[1.30–1.54]) than for cases with positive family history, but
did not differ between index cases of ‘‘small’’ (OR: 1.85
[1.63–2.11]) and ‘‘large’’ families (OR: 1.81 [1.59–2.06]).
Similarly, when comparing affected women from the 52
breast cancer families to healthy population controls, the
PRS was associated with the disease risk (OR: 1.82
[1.55–2.13]), but no difference was seen by the number of
affected first-degree relatives (Table 1, Supplementary
Fig. 1c). The PRS was significantly higher among healthy
women in the 52 breast cancer families than among pop-
ulation controls (OR: 1.29 [1.12–1.48]), consistent with an
association between PRS and positive family history of
breast cancer (Table 1, Supplementary Fig. 1b).
Table 1 Association between the PRS and breast cancer risk in case–control and breast cancer family datasets
Sample group N PRS p value
OR [95 % CI]
Case–control dataset Healthy population controls 1269 Reference
All BC cases 1689 1.56 [1.45–1.68] 9.2E-31
Unselected breast cancer cases 1299 1.49 [1.38–1.62] 3.5E-23
Sporadic breast cancer cases 1020 1.41 [1.30–1.54] 5.1E-16
Index cases from small families 334 1.85 [1.63–2.11] 8.8E-21
Index cases from large families 305 1.81 [1.59–2.06] 2.0E-19
52 breast cancer
families
Affected family members 181 1.82 [1.55–2.13] 1.8E-13
Affected family members with no affected first-degree relatives 50 1.62 [1.22–2.14] 7.7E-4
Affected family members with one affected first-degree relative 58 1.97 [1.52–2.57] 4.0E-7
Affected family members with two affected first-degree relatives 47 1.74 [1.30–2.33] 1.8E-4
Affected family members with three or more affected first-degree
relatives
26 2.05 [1.40–3.02] 2.5E-4
Healthy family members (52 breast cancer families) vs. healthy population controlsa 246 vs.
1269
1.29 [1.12–1.48] 3.4E-4
a Test for association between PRS and positive family history of breast cancer comparing healthy women from the breast cancer families to
healthy population controls
466 Breast Cancer Res Treat (2016) 158:463–469
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PRS as a risk predictor in breast cancer families
The correlation between PRS and BOADICEA score was
0.15 in affected and 0.0099 in healthy women. The asso-
ciation between the PRS and breast cancer risk was
investigated in 427 women from 52 breast cancer families.
Healthy female family members were considered as the
reference group in this analysis. The OR for association
between the PRS and breast cancer in these families was
1.55 [1.26–1.91] (P: 3.3E-5), adjusting for age and the
family history (BOADICEA score). When the model was
further adjusted for the moderate-penetrance mutations, the
PRS OR was 1.59 [1.28–1.98] (P: 2.9E-5, Supplementary
Table 4).
Previously, the relevance of the PRS in risk prediction
has been evaluated by deriving the relative and absolute
risk estimates for women at specific percentiles of the PRS
distribution [5]. We also assigned the affected and healthy
women from the breast cancer families into centiles of the
PRS distribution based on the healthy population controls.
The ORs for breast cancer estimated in the 52 families
were similar in all categories to those obtained in the
BCAC dataset of population-based case–control studies
[5], except for the lowest ten percent, where the number of
study subjects was quite low and the confidence interval
included the published estimate (Fig. 1). The OR for
women in the highest ten percent was 2.71 [1.46–5.03]
(P = 0.0015).
Estrogen receptor status and age at diagnosis
Among cases, lower PRS-values were associated with
higher proportion of ER-negative disease in both
nonfamilial (P = 0.00082) and familial index cases
(P = 0.023), but this trend was not observed within breast
cancer families (P = 0.22)(Supplementary Table 5). No
significant association between PRS and age at diagnosis
was seen in our case–control or breast cancer family
dataset.
Discussion
In this paper, we have investigated the potential of the PRS
to improve risk stratification in the setting of familial breast
cancer. The PRS we constructed used information from 75
variants, almost all breast cancer susceptibility variants
known to date. We tested for association of this PRS with
breast cancer risk among different groups according to
their family history of breast cancer. The PRS was on
average higher in patients with family history of breast
cancer in a first-degree relative than in sporadic cases in the
case–control dataset (Table 1). We neither saw a difference
in the PRS between the ‘‘large’’ and ‘‘small’’ families, nor
an increasing trend with the number of affected first-degree
relatives within the family dataset. Epidemiological studies
have reported life-time risk for women with two affected
first-degree relatives to be higher than for women with only
one affected relative (21.1 vs. 13.3 %) [1]. This difference
was not reflected in a change in PRS, although power for
this comparison was limited in our dataset (Table 1, Sup-
plementary Fig. 1). The PRS was significantly associated
with increased risk of breast cancer within the breast cancer
families, when comparing affected to healthy women.
Furthermore, the PRS was higher among the healthy
women of the breast cancer families compared with healthy
controls from the population (Table 1, Supplementary
Fig. 1), supporting the notion that common genetic risk
variants cluster in breast cancer families.
Our 52 breast cancer families comprised 427 genotyped
and *4000 nongenotyped individuals. The proportion of
affected women in the breast cancer families ranged
between 6 and 67 % per family (median 22 %) (Supple-
mentary Table 2). Two-thirds of the healthy women of the
dataset were first-degree relatives of the breast cancer
cases, and the remainder second- or third-degree relatives.
The BOADICEA risk prediction algorithm is able to cap-
ture complex family structure, including information on
more distant relatives as well as information on ages of
diagnosis or interview, and is more informative than sim-
pler measures of family history. We therefore calculated a
‘BOADICEA score’ as an estimate of the mean
polygenotype for each individual, given their family his-
tory. The correlation between our BOADICEA score and
the PRS in affected women from the 52 breast cancer
families was 0.15, consistent with the relatively small
Fig. 1 Estimated effect sizes (odds ratios: OR with confidence
intervals: CI) by percentile of the PRS in the 52 breast cancer families
Breast Cancer Res Treat (2016) 158:463–469 467
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fraction of the heritability explained by these variants. As
expected, the correlation among the healthy women was
lower (Pearson’s r = 0.0099). These estimates are some-
what higher than that reported recently between PRS and
BOADICEA risk prediction output (0.01 [-0.05–0.07]) by
an Australian study [10]. This could be explained partly by
the different study designs, as the Australian study included
a large number of sporadic cases, and any pedigree data
were collected by interview, whereas we collected family
data systematically from population and cancer registries.
Furthermore, they included in the correlation both breast
cancer cases and healthy controls, which may have masked
an existing correlation in cases.
The PRS was significantly associated with breast cancer
risk in a logistic regression model adjusted for age and the
BOADICEA score (OR: 1.55 [1.26–1.91]). The magnitude of
the effect size associated with the PRS was consistent with the
estimate made in the unselected series of the case–control
dataset (OR: 1.49 [1.38–1.62]) and with the estimate reported
in a recent population-based study (OR: 1.55 [1.52–1.58]) [5],
and provides further support for using the PRS in risk pre-
diction. Furthermore, when the model was adjusted for the
moderate-penetrance mutations in CHEK2, PALB2, and
FANCM, the OR associated with the PRS was very similar
(1.59 [1.28–1.98]) supporting a multiplicative mode of
interaction between the low- and moderate-penetrance
genetic variants. This is been demonstrated explicitly for
CHEK2:c.1100delC and the PRS (Muranen et al. in review),
but further analyses in larger datasets would be needed to
evaluate such interactions for the FANCM and PALB2
variants.
A recent study examined the utility of the PRS for risk
prediction in breast cancer families in the BCFR [27]; our
results are broadly in agreement with the conclusions of
this prospective study. This study used only 24 variants
rather than the full complement of 75 (or 77 as in [5]), so
we would have expected to see a larger effect size in our
study. However, we were not able to directly compare the
effect sizes reported, as the BCFR-study was prospective in
design, used Cox regression for modeling, and the effect of
the PRS was studied in the context of 10-year BOADICEA
risk estimates. In addition, individuals with moderate-
penetrance mutations were excluded from their analyses,
while these individuals were included in our analyses.
Our results on subtype-specific associations are consis-
tent with previous observations that most common genetic
variants are more strongly associated with ER-positive
disease, while fewer ER-negative specific variants have
been identified. Although pathology information in the
familial study was limited, we noted a higher proportion of
ER-negative cancers among women with the lowest PRS in
this study. Noteworthy, none of these cancers were from
carriers of PALB2 or FANCM mutations, which have been
previously associated with ER-negative disease [19, 20]. It
would be of interest to study the pathology of breast can-
cers within families and evaluate any correlations in the
context of the PRS.
The effect sizes associated with the PRS can be used to
derive estimates of the absolute risk of breast cancer according
to PRS [5]. In women with a family history of breast cancer,
the baseline absolute risk of developing breast cancer is
higher. Our observations indicate that the relative risks asso-
ciated with the PRS are similar to those in the general popu-
lation, consistent with a model in which the PRS multiplies the
effects of other familial risk factors. Hence, the effect of the
PRS on the absolute risk of disease will be much greater than
in the general population. For example, if the pedigree-based
familial risk for a woman was about 17 % [9], and her PRS
was in the highest 20 centile, the combined risk would be
30.9 %, moving her from intermediate- to high-risk category
according to UK NICE guidelines [9]. By comparison, women
with no data on family history would have to be in the top
centile of the PRS to have the same absolute risk (*30 %).
We did not find support for the protective effect associated
with low PRS-values (Fig. 1). This may reflect low power, as
few women have very low PRS in the breast cancer families.
However, it might be explained by the presence of yet-
unidentified moderate/high-risk genetic or shared environ-
mental factors [28].
Conclusions
Our results suggest that it would be valuable to combine
the PRS with pedigree-based risk estimation in the context
of familial disease.
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